Abiopharma

Cybin - Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Altimmune to Participate in Upcoming Investor Conferences

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

New Form 6-K - Haleon plc Filed: 2025-08-26 AccNo: 0001654954-25-009994 Size: 40 KB

New Form 8-K - Marker Therapeutics, Inc. Filed: 2025-08-26 AccNo: 0001104659-25-082783 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - EDAP TMS SA Filed: 2025-08-26 AccNo: 0001171843-25-005588 Size: 14 KB

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

General Announcement: Announcement by TMC Life Sciences Berhad - 4Q2025 and FY2025 audited results

Syndax Announces Participation in September Investor Conferences

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma